Beactica Therapeutics initiates IND-enabling studies for glioblastoma drug BEA-17

Swedish precision medicine company Beactica Therapeutics AB has initiated IND-enabling studies for its drug candidate BEA-17. This oral drug targets the epigenetic regulators LSD1 and CoREST and is being developed for the treatment of glioblastoma, an aggressive form of brain cancer.

IND-enabling studies are preclinical and clinical tests required before a new drug can apply for marketing authorization in the United States. BEA-17 is a wholly-owned molecule by Beactica, and its novelty lies in its ability to selectively degrade the LSD1-CoREST complex, which is known to play a key role in the growth and spread of certain cancers, including glioblastoma.

Beactica Therapeutics focuses on developing next-generation therapies that precisely target cancer cell functions. The company believes that degrading the LSD1-CoREST complex offers a novel treatment modality for patients with glioblastoma who have limited options with current therapies.

The company states that the development of BEA-17 represents a significant step towards new treatment strategies for glioblastoma patients. These studies are laying the groundwork for future clinical trials and the evaluation of the drug's potential approval.